Lucky No 5? Pharmacyclics collects $50mn for fifth patient in ibrutinib trial
This article was originally published in Scrip
Five, or maybe 50, must be Pharmacyclics' lucky number: the Sunnyvale, California-based company collected a $50 million milestone payment from Janssen Biotech when the fifth patient was enrolled in the Phase III RESONATE clinical trial evaluating the partners' ibrutinib (PCI-32765) versus GlaxoSmithKline's Arzerra (ofatumumab) in patients with relapsed or refractory lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL).
You may also be interested in...
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.